8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases

American Journal of Respiratory and Critical Care Medicine

Volumn 158, Issue 5 PART I, 1998, Pages 1524-1527

  Montuschi, Paolo ^b   Ciabattoni, Giovanni ^b   Pared, Paolo ^b   Pantelidis, Panagiotis ^b   Du Bois, Roland M ^b   Kharitonov, Sergei A ^b   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LIPID PEROXIDATION; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG SARCOIDOSIS; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

EID: 0031761169     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.158.5.9803102     Document Type: Article

References (35)

1. Cantin, A. M., S. L. North, G. A. Fellis, R. C. Hubbard, and R. G. Crystal. 1987. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J. Clin. Invest. 79:1665-1673.
2. Borok, Z., R. Buhl, G. J. Grimes, A. D. Bokser, R. C. Hubbard, K. J. Holroyd, J. H. Roum, D. B. Czerski, A. M. Cantin, and R. G. Crystal. 1991. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 338:215-216.
3. Behr, J., K. Maier, F. Krombach, and B. C. Adelmann-Grill. 1991. Pathogenetic significance of reactive oxygen species in diffuse fibrosing alveolitis. Am. Rev. Respir. Dis. 144:146-150.
4. McNee, W., and I. Rahman. 1995. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 50(Suppl. 1):S53-S58.
5. Rosen, A., L. Casciola-Rosen, and F. Wigley. 1997. Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr. Opin. Rheumatol. 9:538-543.
6. Schaber, T., M. Rau, H. Stephan, and H. Lode. 1993. Increased number of alveolar macrophages expressing surface molecules of the CD11/CD18 family in sarcoidosis and idiopathic pulmonary fibrosis is related to the production of superoxide anions by these cells. Am. Rev. Respir. Dis. 147:1507-1513.
7. Nielsen, H., J. Frederiksen, D. Sherson, and N. Milman. 1990. Comparison of alveolar macrophage and blood monocyte oxidative burst response in pulmonary sarcoidosis. APMIS 98:401-406.
8. Cassatella, M. A., G. Berton, C. Agostini, R. Zambello, L. Trentin, A. Cipriani, and G. Semenzato. 1989. Generation of superoxide anion by alveolar macrophages in sarcoidosis: evidence for the activation of the oxygen metabolism in patients with high-intensity alveolitis. Immunology 66:451-458.
9. Strausz, J., J. Muller-Quernheim, H. Steppling, and R. Ferlinz. 1990. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 141:124-128.
10. Kiemle-Kallee, J., H. Kreipe, H. J. Radzun, M. R. Parwaresch, U. Auerswald, H. Magnussen, and J. Barth. 1991. Alveolar macrophages in idiopathic pulmonary fibrosis display a more monocyte-like immunophenotype and an increased release of free oxygen radicals. Eur. Respir. J. 4:400-406.
11. Jack, C. I., M. J. Jackson, I. D. Johnston, and C. R. Hind. 1996. Serum indicators of free radical activity in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 153:1918-1923.
12. Lenz, A.-G., U. Costabel, and K. L. Maier. 1996. Oxidized BAL fluid proteins in patients with interstitial lung diseases. Eur. Respir. J. 9:307-312.
13. Kayganich-Harrison, K. A., D. M. Rose, R. C. Murphy, J. D. Morrow, and L. J. Roberts. 1993. Collision-induced dissociation of F2-isoprostane-containing phospholipids. J. Lipid Res. 34:1229-1235.
14. Morrow, J. D., J. A. Awad, H. J. Boss, I. A. Blair, and L. J. Roberts. 1992. Non-cyclooxygenase derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. U.S.A. 89:10721-10725.
15. Morrow, J. D., K. E. Hill, R. F. Burk, T. M. Nammour, K. F. Badr, and L. J. Roberts, II. 1990. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free-radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U.S.A. 87:9383-9387.
16. Morrow, J. D., and L. J. Roberts, II. 1996. The isoprostanes: current knowledge and directions for future research. Biochem. Pharmacol. 51:1-9.
17. Wang, Z., G. Ciabattoni, C. Creminon, J. Lawson, G. A. Fitzgerald, C. Patrono, and J. Maclouf. 1995. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J. Pharmacol. Exp. Ther. 275:94-100.
18. Morrow, J. D., B. Frei, A. W. Longmire, J. M. Gaziano, S. M. Lynch, Y. Shyr, W. E. Strauss, J. A. Dates, and L. J. Roberts, II. 1995. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. N. Engl. J. Med. 332:1198-1203.
19. Morrow, J. D., K. P. Moore, J. A. Awad, M. D. Ravenscraft, G. Marini, K. F. Badr, R. Williams, and L. J. Roberts, II. 1993. Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. J. Lipid Mediat. 6:417-420.
20. Stein, C. M., S. B. Tanner, J. A. Awad, L. J. Roberts, II, and J. D. Morrow. 1996. Evidence for a free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 39:1146-1150.
21. Wells, A. U., D. M. Hansell, M. B. Rubens, J. B. Cailes, C. M. Black, and R. M. du Bois. 1997. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis. Am. J. Respir. Crit. Care Med. 155:1657-1664.
22. Mathieson, J. R., J. R. Mayo, C. A. Staples, and N. I. Muller. 1989. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 171:111-116.
23. Tung, K. T., A. C. Wells, M. B. Rubens, J. M. B. Kirl, R. du Bois, and D.M. Hansell. 1993. Accuracy of typical computed tomography appearances of fibrosing alveolitis. Thorax 48:334-338.
24. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. 1980. Arthritis Rheum. 23:581-590.
25. Crystal, R. G., P. B. Bitterman, S. I. Rennard, A. J. Hance, and B. A. Keogh. 1984. Interstitial lung disease of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. N. Engl. J. Med. 310:154-166.
26. Haslam, P. L., C. W. G. Turton, B. Heard, A. Lokuszek, J. V. Collins, A. J. Salsbury, and M. Turner-Warwick. 1980. Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. Thorax 35:9-18.
27. Behr, J., C. Vogelmeier, T. Beinert, M. Meurer, F. Krombach, and G. Fruhmann. 1996. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am. J. Respir. Crit. Care Med. 154:400-406.
28. 2α in the airways of human subjects. Am. J. Respir. Cell Mol. Biol. 9:568-572.
29. Kharitonov, S. A., F. K. Chung, D. J. Evans, B. J. O'Connor, and P. J. Barnes. 1996. The elevated level of exhaled nitric oxide in asthmatic patients is mainly derived from the lower respiratory tract. Am. J. Respir. Crit. Care Med. 153:1773-1780.
30. Roberts, L. J., II, and J. D. Morrow. 1997. The generation and actions of isoprostanes. Biochim. Biophys. Acta 1345:121-135.
31. Patrono, C., and G. A. Fitzgerald. 1997. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscl. Thromb, Vasc. Biol. 17:2309-2315.
32. 2 alpha. J. Biol. Chem. 270:9800-9808.
33. 2 alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J. Biol. Chem. 271:8919-8924.
34. 2 alpha in vitro and in vivo via the cyclooxygenases. J. Pharmacol. Exp. Ther. 282:1658-1665.
35. Delanty, N., M. Reilly, D. Pratico, D. J. Fitzgerald, J. A. Lawson, and G. A. FitzGerald. 1996. 8-Epi-PGF2α: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br. J. Clin. Pharmacol. 42:15-19.